CABLIVI▼ (caplacizumab) is the first licensed disease-modifying treatment for aTTP1
The National Institute for Health and Care Excellence (NICE) has recommended the use of CABLIVI in line with its full indication.1
CABLIVI is indicated for the treatment of adults and adolescents of 12 years of age and older weighing at least 40 kg experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange (PEX) + immunosuppression (IMS).2
View the most frequent adverse events, warnings and precautions associated with CABLIVI.
Consult the recommended dosing schedule for CABLIVI.
Mechanism of action
Discover CABLIVI’s innovative, disease-modifying mechanism of action (MOA).
CABLIVI: Maximise your efficacy in aTTP treatment.
CABLIVI has been assessed in two controlled Phase III clinical trials (Scully M, et al. 2019 and Coppo P, et al. 2021).3,4 Pooled analysis of the data from the Phase II TITAN5 and Phase III HERCULES3 trials was recently published by Peyvandi F, et al. 2021 in Blood Advances, confirming the findings from the other two studies in terms of mortality, refractory disease and safety data.6
CABLIVI plus PEX+IMS helps patients achieve a platelet response when they need it most.2–4
CABLIVI’s safety profile has been investigated in controlled clinical trials and is consistent with its mechanism of action in aTTP.2
- Bleeding events associated with CABLIVI were generally self-limited, and all events in the Phase III clinical trial resolved, most without intervention2,3
- CABLIVI plus PEX+IMS had a lower discontinuation rate (7% [5/71‡]) vs. PEX+IMS alone (12.3% [9/73])3
‡1 patient withdrew from the trial.3
The most frequent adverse reactions (very common ≥1/10) reported were epistaxis, headache, gingival bleeding, urticaria, pyrexia and fatigue.2,3
CABLIVI plus PEX+IMS
At least 1 treatment-emergent
adverse event (TEAE)
95.8% (68) 90.3% (66) Epistaxis 32.4% (23) 2.7% (2) Gingival bleeding 18.3% (13) 1.4% (1)
• In case of active, significant bleeding, treatment with CABLIVI should be interrupted and only restarted upon the advice of a physician experienced in the management of thrombotic microangiopathies2
• Close clinical monitoring and benefit/risk assessment must be completed for initiation or continuation of CABLIVI treatment with anticoagulants/heparin as there have been no interaction studies evaluating the use of CABLIVI with oral anticoagulants/high dose heparin2
• In patients with underlying coagulopathies, the use of CABLIVI must be accompanied by close clinical monitoring2
• Patients undergoing surgery/dental procedures should be advised to inform their physician/dentist that they are using CABLIVI and treatment should be stopped at least 7 days before the planned intervention2
BSH webinar: Improvements in follow-up
CABLIVI dosing schedule.
CABLIVI is administered by both intravenous (IV) and subcutaneous (SC) injection and should be initiated and supervised by physicians experienced in the management of patients with thrombotic microangiopathies.2
BSH webinar: Improvements in follow-up
CABLIVI: is an innovative therapy designed to act on the underlying disease pathology of aTTP.2
CABLIVI is a humanised nanobody that rapidly binds to the A1 domain of von Willebrand factor (vWF) preventing the ultra-large von Willebrand factor (ULvWF) mediated platelet adhesion characteristic of aTTP.2,9
Watch the animation below for a reminder of the pathophysiology of aTTP, or see About aTTP.
Educational animation: pathogenesis of aTTP
ADAMTS13, a disintegrin and metalloprotease with thrombospondin type 1 motif, member 13; aTTP, acquired thrombotic thrombocytopenic purpura; BSH, British Society for Haematology; ICU, intensive care unit; IMS, immunosuppression; IV, intravenous; NICE, National Institute for Health and Care Excellence; PEX, plasma exchange; SC, subcutaneous; ULvWF, ultra-large von Willebrand factor; vWF, von Willebrand factor.